Table 4

Multivariable Cox regression analyzing the association of bridging therapy use with overall survival (N=225)

VariableHR (95% CI)SEP value
Months from relapse to CAR T-cell infusion0.71 (0.53 to 0.95)0.100.019
ECOG performance status1.25 (0.97 to 1.61)0.160.082
LDH >500 (U/L, prior to CAR T-cell infusion)1.04 (0.58 to 1.87)0.310.901
CRP >30 (mg/L, prior to CAR T-cell infusion)1.78 (1.11 to 2.86)0.430.017
Bridging therapy use1.97 (1.24 to 3.14)0.470.004
Dexamethasone dose (dg) from days 0–311.12 (1.01 to 1.24)0.060.028
  • .CAR, chimeric antigen receptor; CRP, C-reactive protein; dg, decigram; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.